Michael F. Murphy, M.D., Ph.D. — Chief Medical and Scientific Officer, Worldwide Clinical Trials

Chief Medical and Scientific Officer, Worldwide Clinical Trials

 

 

 

 

Michael F. Murphy, M.D., Ph.D., is the Chief Medical and Scientific Officer for Worldwide Clinical Trials, an international, multiservice clinical research organization providing research services for devices and pharmaceutical products across all phases of clinical development in multiple therapeutic areas. During a career of 30 years, positions within the pharmaceutical industry emphasized the integration of medical and scientific acumen with operational excellence.

 

Publications focusing upon clinical trial methodology span a spectrum of concepts from translational medicine through commercialization. Representative examples include an adaptive dosing paradigm in early phase clinical research (An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations. J Biopharm Stat. 2009; 19 (2):247-55), research and development strategies on healthcare utilization (Pharmaceutical R&D strategy and the transition to personalized healthcare planning. American Health and Drug Benefits. 2010. 3(2): S130-S136), clinical research in the emergency setting (The emergency environment’s untapped potential. International Clinical Trials.2011.68-72) and strategic program development options in multiple therapeutic areas (Postapproval development options in COPD: a case study in value-based healthcare systems. American Health and Drug Benefits. 2011. 4 (1): 19-23; Methods in Medicine and PSCK9 Inhibitors: Design, Execution and Inferences Based upon Cardiovascular Outcome Trials. 2016. submitted). Joint authorship in peer reviewed publications reflect contributions to design, analysis and interpretation for a number of industry sponsored interventional studies (A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry. 2011 Jun 1; 69(11):1075-82; Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer’s disease. J Alzheimers Dis. 2012; 29(3):527-35).

 

Prior to joining WCT, Dr. Murphy was Chief Medical Officer, and Senior Vice President of Discovery and Development at TorreyPines Therapeutics Inc. Contributions emphasized translational research for small molecules in neurodegeneration and analgesia (GWAS, γ secretase modulator, AMPA/kainate receptor antagonist, selective M1 agonists). He has served as President and Chief Medical and Scientific Officer of a Clinical Research Organization in a division of UnitedHealth Group. During his tenure, this CRO was rated “number one” in the United States by CenterWatch.

 

Dr. Murphy has participated in the IND application process for multiple small molecules and biologics: Alzheimer’s disease and phenotypes (e.g., most recent, disease modification therapy, amnestic MCI, 2014, 2016), amyotrophic lateral sclerosis, analgesia (nociceptive and neuropathic pain), acute migraine, chemotherapy-induced neuropathy, depression, diabetic peripheral neuropathy, idiopathic small fiber painful neuropathy, male erectile disorder, multi-infarct dementia, narcolepsy post-polio syndrome, schizophrenia, xerostomia in Sjögren’s Disease (2007), psychosis in Velo-cardio-facial syndrome (2009), frequency dysuria syndrome (2010), generalized anxiety disorder (2014) and major depression (2014). NDA approvals exist in depression, Alzheimer’s disease, and narcolepsy (Provigel ®). Interest in orphan disease discovery, development and commercialization characterize recent activities (56 studies) within diverse indications such as cystic fibrosis, Duchenne muscular dystrophy, Lambert–Eaton Myasthenic syndrome, Lupus Nephritis, sickle-cell disease (Murphy, M. Riches, C. Rarity, disease heterogeneity, and a mandate to demonstrate value. In, the Battle for Market Access. PharmaFocus. September 2014:16-17). He has served as a consultant to Duke Clinical Research Institute (DCRI), the Michael J. Fox Foundation, and a number of pharmaceutical and biotechnology companies.

 

He is boarded in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University, and the Mt. Sinai School of Medicine. He is Research & Development Editor for A_m_e_r_i_c_a_n_ _H_e_a_l_t_h_ _&_ _D_r_u_g_ _B_e_n_e_f_i_t_s_™ _a publication which focuses upon cost, quality, and access in the transition of novel diagnostics and therapeutics from discovery to commercialization. As a lecturer within the Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology (HST) since 1997, he contributed to the curriculum for a two-year Clinical Investigator Training Program. This tradition continues under the auspices of the Program in Clinical and Translational Science (PCaTS).

He was named the Clinical Research & Excellence (CARE) Lifetime Achievement Award recipient for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career.

 

610-964-2007 (voice); 610-235-9702 (mobile)

michael.murphy@worldwide.com